Kornimate/medical-research-clean huggingface dataset:
mesotherapy in the treatment of chronic migraine

Conditions: Chronic Migraine, Headache

Summary: mesotherapy is a type of injection frequently used in clinics. it is a treatment procedure that involves the injection of some drugs under the skin or into the skin. mesotherapy is used in musculoskeletal system diseases, but it is reported that the effects of its use in migraine are uncertain.

migraine is one of the types of headaches. for the diagnosis of chronic migraine, the headache must last more than 15 days. nerve blocks, oral medication and neuromodulation are recommended for migraine treatment.mesotherapy is a type of injection frequently used in clinics. it is a treatment procedure that involves the injection of some drugs under the skin or into the skin. mesotherapy is used in musculoskeletal system diseases, but it is reported that the effects of its use in migraine are uncertain. this study was planned to show the effectiveness of mesotherapy in patients with migraine.

Eligibility criteria:
inclusion criteria: - clinical diagnosis of chronic migraine disease exclusion criteria: * infection disease * thyroid disease * anemia disease * systemic disease

Keywords: mesotherapy chronic migraine pain muscle headache
study to investigate the analgesic efficacy of a single dose of azd1940

Conditions: Pain

Summary: the primary aim of this study is to investigate if azd1940 can relieve the pain induced by the surgical removal of one lower wisdom-tooth. this will be done by comparing the effect of azd1940 to placebo ("inactive substance") on pain. a number of patients will instead receive the common painkiller naproxen for comparison purposes. rescue medication, acetaminophen, will be allowed if a need for additional painkillers would arise. a number of patients will receive naproxen as control.


Eligibility criteria:
inclusion criteria: * patients scheduled for surgical removal of one partial or complete impacted mandibular third molar. * provision of signed informed consent. * healthy males or non-fertile females. exclusion criteria: * history of somatic disease/condition, which may interfere with the objectives of the study, as judged by the investigator. * history of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the diagnostic and statistical manual of mental disorder, 4th edition.

Keywords: analgesic effect molar extraction
ultrasound-guided percutaneous biliary drainage with primary metal implantation by endoscopic luminal guidance

Conditions: Bile Duct Obstruction, Extrahepatic

Summary: in a recently published meta-analysis (sharaiha, gastrointestinal endoscopy, 2017), it is reported that percutaneous transhepatic biliary drainage (ptbd) is less clinical successful, causes more adverse events and needs more re-interventions than endoscopic ultrasound guided biliary drainage (eubd) in patients with malignant, extrahepatic bile duct obstruction. the conclusion was, that eubd should be prefered in this clinical setting in future. an improved technique of ptbd may provide better results for coming comparative studies. the investigators of this retrospective study therefore analyzed all ptbds that were performed in a period of nine years in a tertiary referral hospital. in this cohort, the analysis focused on ptbds with primary metal stent implantation by endoscopic luminal guidance.

when endoscopic retrograde cholangiopancreaticography (ercp) is not successful or is not possible to be performed due to anatomical reasons (altered anatomy after abdominal surgery) in patients with malignant extrahepatic bile duct obstruction, an alternative method is necessary for biliary drainage. in a recently published meta-analysis (sharaiha, gastrointestinal endoscopy, 2017), it is reported that percutaneous transhepatic biliary drainage (ptbd) is less clinical successful, causes more adverse events and needs more re-interventions than endoscopic ultrasound guided biliary drainage (eubd) in patients with malignant, extrahepatic bile duct obstruction. the conclusion was, that eubd should be prefered in this clinical setting in future. an improved technique of ptbd may provide better results for coming comparative studies. the investigators of this retrospective study therefore analyzed all ptbds that were performed in a period of nine years in a tertiary referral hospital. in this cohort, the analysis focused on ptbds with primary metal stent implantation by endoscopic luminal guidance considering technical and clinical success, access route, procedure time, fluoroscopic time, radiation exposure, adverse events and survival probability in an observation time of six months.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * not curatively operable, malignant disease with proximal or distal bile duct obstruction * elevated serum bilirubin level and/or elevated alkaline phosphatase to at least a twofold degree * histologically verified diagnosis * at least one cross-sectional imaging method like computed tomography or magnetic resonance imaging of the abdomen has to be performed exclusion criteria: * uncorrectable coagulopathy (prothrombin time \ 50 sec. * advanced tumor disease with limited life expectancy (\< 1 month) * diffuse liver metastasis * pregnant or breast feeding women * potentially curatively, operable, malignant bile duct obstruction * diseases which can be cured by chemotherapy (for example aggressive non hodgkin-lymphoma).

Keywords: percutaneous biliary drainage
valganciclovir to reduce t cell activation in hiv infection

Conditions: HIV Infections; Cytomegalovirus Infections

Summary: the purpose of this study is to determine whether treatment with valganciclovir decreases t cell activation levels among hiv-infected patients with asymptomatic cytomegalovirus (cmv) co-infection, potentially improving immune responses to antiretroviral therapy.


Eligibility criteria:
inclusion criteria: * infection with hiv \>1 year in duration. * age \>18 * cytomegalovirus (cmv) antibody positive. * all cluster of differentiation 4 (cd4)+ t cell counts in the last year and at screening \<350 cells/mm3 * on a stable highly addictive antiretroviral therapy (haart) regimen (dhhs definition) for the preceding 6 months. * 90% adherence to antiretroviral therapy within the preceding 30 days. * females of childbearing potential must have a negative serum pregnancy test at screening and all subjects must agree to use a double-barrier method of contraception throughout the study period. * screening %cluster of differentiation 38 (cd38)+ human leukocyte antigen-d-related (hla-dr)+ cluster of differentiation 8 (cd8)+ t cells \>10% exclusion criteria: * patients intending to modify antiretroviral therapy in the next 16 weeks. * serious illness requiring hospitalization or parental antibiotics within preceding 3 months. * evidence of active symptomatic cmv end-organ disease. * treatment with valganciclovir or ganciclovir in the past 30 days. * concurrent treatment with immunomodulatory drugs. * concurrent treatment with nephrotoxic drugs * screening absolute neutrophil count \<1,000 cells/mm3, platelet count \<100,000 cells/mm3, hemoglobin \< 8mg/dl, estimated creatinine clearance \<50 ml/minute. * men who are considering having children will also be excluded given potential effects of valganciclovir on spermatogenesis. * pregnant or breastfeeding women

Keywords: hiv cmv t cell activation valganciclovir
su5416 in treating patients with metastatic melanoma that has been previously treated

Conditions: Recurrent Melanoma; Stage IV Melanoma

Summary: su5416 may stop the growth of malignant melanoma by stopping blood flow to the tumor. phase ii trial to study the effectiveness of su5416 in treating patients who have metastatic melanoma that has been previously treated

primary objectives: i. determine the objective response rate and stabilization of disease rates of patients with previously treated metastatic melanoma treated with su5416. ii. determine the toxicity of su5416 in this patient population. iii. determine the median and overall survival and time to progression in these patients receiving this treatment. outline: this is a multicenter study. patients receive su5416 iv over 60 minutes twice weekly for 4 weeks. treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression. patients are followed weekly for 4 weeks. projected accrual: a total of 14-35 patients will be accrued for this study within 18-24 months.

Eligibility criteria:
inclusion criteria: * histologically confirmed melanoma with documented metastatic disease * in transit metastases allowed * lesion accessible for biopsy * measurable disease * greater than 20 mm by conventional techniques orgreater than 10 mm by spiral ct * documented progressive disease by radiologic study or physical examination * known history of cns metastasis who have had treatment, are neurologicallystable, and do not require intravenous antibiotics or anticonvulsants eligibleprovided oral steroids are not required and brain scan (ct or mri) showsabsence of active or residual disease * if neurologic signs or symptoms suggestive of cns metastasis, negative brain scan required * performance status - who 0-2 * at least 12 weeks * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin no greater than 1.5 mg/dl * transaminases no greater than 2.5 times upper limit of normal * creatinine no greater than 1.5 mg/dl * creatinine clearance at least 60 ml/min * no uncompensated coronary artery disease * no history of myocardial infarction or severe/unstable angina within past 6 months * no severe peripheral vascular disease associated with diabetes mellitus * no deep venous or arterial thrombosis within past 3 months * no pulmonary embolism within past 3 months * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no other significant uncontrolled underlying medical or psychiatric illness * no serious active infections * no other malignancy within past 5 years except for curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix * no history of severe allergic or anaphylactic reactions to paclitaxel or docetaxel * no other concurrent chemotherapy * no other concurrent investigational antineoplastic drugs * see disease characteristics * no prior radiotherapy to only site of measurable disease * at least 4 weeks since prior radiotherapy and recovered * no concurrent radiotherapy * no greater than 1 prior therapy for metastatic disease * at least 4 weeks since prior therapy
passport to freedom: health and housing

Conditions: Trauma

Summary: the purpose of the passport to freedom (p2f) health and housing is to provide formerly homeless women a supportive group to process the impact of trauma on the women's overall health and wellbeing, learn strategies to reduce the symptoms of trauma and stress, and increased ability to cope with everyday stress while maintaining permanent housing.

the proposed project will use a mixed method design to examine the feasibility and effectiveness of the passport to freedom (p2f) program, an intervention for formerly homeless women currently housed through a supportive permanent housing program. p2f involves: three 2-hr sessions to promote physical and emotional wellbeing through mindfulness techniques and health promotion activities; two home visits to provide individualized sessions with a nurse and a community health navigator; and a follow-up session 4 weeks after intervention to discuss the women's perception of the intervention. by the end of the program, women will have improved emotional self-regulation in response to everyday stress, positive perception of managing women's overall health, and increased confidence in maintaining stable housing.

Eligibility criteria:
inclusion criteria: * women 18 years to 55 years, may be parents * able to read and write english * formerly homeless and currently living in permanent supportive housing through the women's housing coalition program. exclusion criteria: * under 18 years of age * inability to speak or write english
the optimal timing for cerclage removal

Conditions: Respiratory Disease of A Newborn

Summary: women with a history of cervical insufficiency can be managed with elective cervical cerclage placed at the beginning of the second trimester. the mcdonald technique is the most commonly used. though lack a robust scientific evidence, the cerclage is removed electively at 36-37 weeks of gestation in order to avoid maternal cervical laceration. in addition, the incidence of spontaneous delivery is nearly 20% within 72 hours after ceclage removal, thus elective cerclage removal at 36-37 weeks may also put the newborns at complications associated with iatrogenic late preterm/early term delivery

the optimal timing of cervical cerclage removal is yet unclear. in the present study we will evaluate maternal and neonatal outcome variables after elective removal of the cerclage, and may suggest a gestational week cut-off for optimal cerclage removal/ primary outcome: neonatal respiratory morbidity after cerclage removal. the respiratory outcome will be compared across each gestational week of delivery after cerclage removal, that is; group 1 (36-36.6 weeks), group 2 (37-37.6 weeks), group 3 (38-38.6 weeks), group 4 (beyond 39 weeks). secondary outcomes: time interval between cerclage removal and gestational age of delivery.

Eligibility criteria:
inclusion criteria: * singleton pregnancies * elective or emergent cerclage in the current pregnancy * cerclage that was removed after 36 weeks of pregnancy exclusion criteria: * multiple pregnancies * major congenital anomalies * cerclage removal before 36weeks of pregnancy

Keywords: rds cerclage cervix insufficiency
acute cognition and exercise

Conditions: Obesity

Summary: the central hypothesis is that, while both groups will benefit from the exercise session, participants with obesity will exhibit greater gains in cognitive control, relative to healthy weight adults. additionally, it is anticipated that the benefits of a single bout of exercise for cognitive control will be mediated by changes in exercise-induced myokines. these hypotheses will be tested by accomplishing three aims: aim 1: elucidate the changes in cognitive control following an acute bout of exercise, relative to a sedentary condition, in persons with and without obesity. aim 2: to examine the effect of a single bout of exercise, relative to a sedentary condition, on myokines known to have neuroprotective effects i.e., bdnf and ctsb in both healthy weight and individuals with obesity. aim 3: to link changes in exercise-induced myokines (i.e., bdnf and ctsb) to changes in cognitive function, following a single bout of exercise.

18 adults with healthy weight (bmi 18.5-25.0kg/m2) and 18 adults with obesity (bmi 30.0kg/m2) will be asked to complete a counter-balanced crossover trial. after initial baseline testing, participants will be asked to complete either an acute exercise bout or sedentary control session in a counter-balanced order. a cognitive testing battery accompanied by an electroencephalogram (eeg) will be administered following each session. blood samples will be collected prior to, during, and following each throughout each testing condition.

Eligibility criteria:
inclusion criteria: * between ages 18 and 35 * no prior diagnosis of neurological disorders (e.g., autism spectrum disorder) * no prior diagnosis of metabolic disease (e.g., diabetes, cardiovascular disease) * no physical disability that would preclude the participant from completing a vo2max test * corrected vision (based on the minimal 20/20 standard needed to complete cognitive tasks) * not pregnant * bmi between 18.5 and 25.0 kg/m2, or bmi greater than 30.0 kg/m2 * readiness for exercise (determined through par-q) exclusion criteria: * \ 35 years * diagnosis of neurological disorders (e.g., autism spectrum disorder) * diagnosis of metabolic disease (e.g., diabetes, cardiovascular disease) * physical disability that would preclude the participant from completing a vo2max test * lack of corrected vision (based on the minimal 20/20 standard needed to complete cognitive tasks) * pregnancy * bmi less than 18.5 kg/m2 or bmi greater than 25.0 but less than 30.0 kg/m2

Keywords: myokine cognition ctsb bdnf exercise
cognitive-motor training for pd

Conditions: Parkinson's Disease

Summary: this study will evaluate gait when individuals with parkinson's disease (pd) are walking and how walking changes when challenged to perform a functional cognitive task simultaneously. by looking at walking alone and walking with varying cognitive loads the investigators will be able to determine motor and cognitive factors vulnerable to interference in pd. each is important to understand so that training can address components of walking that become impaired when someone is distracted by a common cognitive task and so that the intensity of treatment matches the level of task difficulty. using this initial data, the investigators will establish a protocol to improve walking taking into account the unique features of pd, including bradykinesia, freezing of gait, stiffness, and problems with memory and attention. the investigators will evaluate the potential for this treatment to improve walking and improve or maintain cognitive abilities necessary to multitask.

in this study participants will be asked to participate in a training study to examine whether a new walking intervention that combines cognitive training with walking on a treadmill improves walking more than gait training or cognitive training alone. participants with parkinson's disease (pd) will come to the lab for a complete gait assessment using a motion analysis system that will record leg motion and muscle activity during comfortable walking. during the initial evaluation, participants will also complete cognitive assessments and surveys about community activities and quality of life related to pd. participants will be divided into two training groups and asked to come to the lab three times a week for four weeks during the intervention. one week and one month after training, participants will return to the lab to complete all the same assessments that were performed during the initial visit. the results of the three testing sessions (initial, one week and one month) will be compared between and within groups to see if any of the interventions provided unique benefits to the health of persons with pd.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease with our without cognitive impairment * ambulatory for at least 200 feet without an assistive device (cane, walker, etc) exclusion criteria: * recent orthopedic injury (e.g., fracture, sprain, muscle pull, herniated disc) * concurrent neurological illnesses including stroke, brain cancer, spinal cord injury, and diabetic neuropathies. * cardiac insufficiency limiting ability to participate in walking study

Keywords: walking parkinson's disease physical therapy falls memory attention multitasking exercise
a study of tirzepatide (ly3298176) in participants with type 2 diabetes who have obesity or are overweight

Conditions: Type 2 Diabetes; Overweight; Obesity

Summary: this is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. the main purpose is to learn more about how tirzepatide affects body weight. the study will last 79 weeks (22 visits).


Eligibility criteria:
inclusion criteria: * have type 2 diabetes (t2dm) with hba1c ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. t2dm may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) except dipeptidyl peptidase 4 (dpp-4) inhibitors or glucagon like peptide-1 receptor agonists (glp-1 ras) * have a bmi of ≥27 kg/m² * are overweight or have obesity * have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight * are at least 18 years of age and age of majority per local laws and regulations exclusion criteria: * have type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except t2dm * have at least 2 confirmed fasting self-monitoring blood glucose (smbg) values \>270 mg/dl(on 2 nonconsecutive days) prior to visit 3 * have proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment * have self-reported change in body weight \>5kg within 3 months prior to screening * have had a history of chronic or acute pancreatitis * change in body weight greater than 5 kg within 3 months prior to starting study * obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity * family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2) * history of significant active or unstable major depressive disorder (mdd) or other severe psychiatric disorder within the last 2 years * any lifetime history of a suicide attempt

Keywords: metabolism and nutrition disorder
trial of a multilevel intervention to increase colorectal cancer screening

Conditions: Colorectal Cancer

Summary: this study will assess the effectiveness of a culturally-responsive intervention to increase colorectal cancer (crc) screening among latino immigrants in a primary care clinic setting of a large municipal hospital in new york city. propose a randomized, control trial to determine if a video-based intervention, that educates and activates the patient and the provider via the patient, will increase rates of crc screening referrals compared to a control group. colorectal cancer remains one of the most prevalent cancers among the general population, as well as in the latino population, in the united states. there are serious disparities in crc screening rates between different races and socio-demographic populations (american cancer society: colorectal cancer facts and figures - special edition 2005). latino immigrants are one of the populations most affected by the lack of screening, reducing their relative benefit from preventive crc services. this study will use a modified version of an intervention developed and studied by pignone (11), with changes made to be tailored specifically to the latino immigrant population. the outcomes measured will include referral for crc screening and adherence with providers' referrals. in addition, the investigators will measure screening rates for other cancer screening tests to assess if the crc intervention displaces or facilitates other cancer screening. a sample of latino immigrants seeking care at the primary care clinic of bellevue hospital will be accrued through a process of consecutive sampling until reaching the proposed sample size of 101 patients in each group (alpha 0.05 and power of 80%). to analyze the effectiveness of the intervention the investigators will use the z-test and will report the difference in proportion between the intervention and the control group with a 95% ci, adjusting for intra-class correlations and covariates. a repeated measurement analysis with logistic regression will be used to examine the effects of covariates.


Eligibility criteria:
inclusion criteria: * adult latino immigrants * men and women * 50 years and older * having had at least 2 previous visits to the primary care clinic in the past 2 years exclusion criteria: * personal or family history of colorectal cancer. * had fecal occult blood testing (fobt) in the past year, or flexible sigmoidoscopy or barium enema in the past 5 years, or colonoscopy in the past 10 years. * lower gastrointestinal symptoms, including bleeding, pain, diarrhea and/or constipation. * too ill to participate * any cancer diagnosis other than non-melanoma skin cancer.